<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947635</url>
  </required_header>
  <id_info>
    <org_study_id>Islet-Liver-MTC</org_study_id>
    <nct_id>NCT00947635</nct_id>
  </id_info>
  <brief_title>Cholesterol and Fatty Acid Synthesis in Islet and Liver Transplant Patients and Effect of Dietary Intervention</brief_title>
  <official_title>Cholesterol and Fatty Acid Synthesis in Islet and Liver Transplant Patients and Effect of Dietary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to investigate possible mechanisms of increased blood lipid levels following
      transplantation, and also to see if a comprehensive dietary intervention is effective in
      reducing blood lipid levels in post-transplant patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-transplantation patients frequently have an increase in blood lipid levels presumed to
      be due to immunosuppressive agents, however it is currently unknown the mechanisms by which
      this occurs. Dietary interventions have frequently been unsuccessful in these patients, which
      may be due to single-nutrient interventions and lack of support and guidance. This research
      will use stable isotope methods to estimate cholesterol and fatty acid synthesis to determine
      if these pathways are affected by immunosuppression in patients before and after islet and
      liver transplant. In addition, it will be determined if a multi-nutrient dietary intervention
      will be implemented post-transplant can reduce blood lipid levels in to prevent further
      polypharmacy these patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cholesterol and fatty acid synthesis</measure>
    <time_frame>Pre-transplant, post-transplant (&gt;3 months after transplant, up to 2 years) and post-dietary intervention (1 month after post-transplant measurement)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood lipid levels</measure>
    <time_frame>Pre-transplant, post-transplant (&gt;3 months after transplant, up to 2 years) and post-dietary intervention (1 month after post-transplant measurement)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Immunosuppression</condition>
  <condition>Hyperlipidemias</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Islet transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>People with Type 1 diabetes undergoing islet transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>People with liver failure undergoing liver transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy normal people which serve as control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary intervention - supplements</intervention_name>
    <description>Supplement bar &amp; spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels</description>
    <arm_group_label>Islet transplant</arm_group_label>
    <arm_group_label>Liver transplant</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  on islet or liver transplant list

          -  post-transplant &gt;3 months

          -  physically able to participate in study and intervention

        Exclusion Criteria:

          -  &lt; 18 years of age

          -  family history of premature cardiovascular disease or familial hyperlipidemia (control
             subjects)

          -  cholestatic diseases (liver transplant patients)

          -  type 2 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael T Clandinin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2009</study_first_posted>
  <last_update_submitted>July 24, 2009</last_update_submitted>
  <last_update_submitted_qc>July 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Michael T. Clandinin</name_title>
    <organization>University of Alberta</organization>
  </responsible_party>
  <keyword>Type 1 diabetes</keyword>
  <keyword>Transplants</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Nutrition Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

